Raymond James Financial
XRTX

Raymond James Financial’s XORTX Therapeutics XRTX Stock Holding History

Raymond James Financial’s Portfolio XRTX Stock Details XRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$453 – 6825
2025
Q2 		$453 Buy
+100
New +$472 ﹤0.01% 6682

Other funds holding XRTX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Raymond James Financial's XRTX Position: Q3 2025 in Review

Raymond James Financial sold out of XORTX Therapeutics (XRTX) in Q3 2025, closing a stake of 100 shares — an estimated $453 sold.

Raymond James Financial first reported a position in XRTX in Q2 2025 and held it in 1 quarter. The position peaked at $453 in Q2 2025. 5 funds tracked by Wall St. Rank hold XRTX as of Q3 2025.

  • Raymond James Financial reported no remaining XORTX Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 100 XORTX Therapeutics shares in Q3 2025, an estimated $453.
  • Raymond James Financial first reported a position in XORTX Therapeutics in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's XORTX Therapeutics position peaked at $453 in Q2 2025.
  • 5 funds tracked by Wall St. Rank held XORTX Therapeutics as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.